Salix Pharma, Progenics in RELISTOR worldwide license agreement
The methylnaltrexone license includes intellectual property from the University of Chicago, Progenics Pharmaceuticals and Wyeth Pharmaceuticals, including patents and applications with expiration dates that will range from 2017
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.